In addition, compared with the control group, the E2F1 protein level was upregulated in the E2F1-OE and miR-485-5p inhibitor groups, and downregulated in the mimic group; CDDP treatment facilitated the effect of miR-485-5p mimic and offset the effect of the inhibitor, suggesting that miR-485-5p is upstream of E2F1 under CDDP treatment in glioblastoma (Figure 3f and g). The gene discussed is E2F1; the disease is glioblastoma.